uniQure N.V. (QURE)

In September 2025, uniQure's stock surged after AMT-130 showed a statistically significant slowing of disease progression in Huntington's disease and the company raised approximately $323.7 million through a public follow-on offering. In November 2025, uniQure released its Q3 earnings, reporting an EPS of -$1.38 and quarterly revenue of $3.70 million, both falling below analyst estimates, and a regulatory update on AMT-130 introduced uncertainty regarding the timing of its BLA submission. In December 2025, institutional ownership saw a slight downtrend. In January 2026, uniQure announced a Type A Meeting with the FDA, and investment banks reiterated their ratings on uniQure stock. In February 2026, uniQure announced updated data from its trial of AMT-191 for Fabry disease, leading to a gain in the company's stock.

There is no direct information available indicating demand seasonality for uniQure NV's products or services. Demand for its specialized medical treatments is typically driven by patient need and regulatory approvals rather than seasonal fluctuations.

uniQure NV is a Netherlands-based biotechnology company focused on developing and commercializing gene therapies for rare diseases. Its major approved product is HEMGENIX, a gene therapy for hemophilia B. The company's pipeline includes AMT-130 for Huntington's disease, AMT-260 for mesial temporal lobe epilepsy, AMT-162 for superoxide dismutase 1-triggered amyotrophic lateral sclerosis (ALS), and AMT-191 for Fabry disease. uniQure also has ongoing research programs for AMT-161 (ALS), AMT-240 (autosomal dominant Alzheimer's disease), and AMT-210 (Parkinson's disease).

uniQure NV is headquartered in Amsterdam, Netherlands, and develops treatments for patients in the United States. In 2025, uniQure shifted to a fully outsourced manufacturing model, changing its direct environmental footprint to a research-focused biotech. Its indirect environmental footprint is now linked to the sustainability performance of Genezen, which operates uniQure's former facility.

uniQure is perceived as a biotechnology innovator with a "Moderate Buy" rating from analysts. Positive clinical trial data for gene therapies like AMT-130 and AMT-191 have positively impacted its reputation and stock price. However, unexpected FDA feedback regarding AMT-130 introduced uncertainty, and the company's financials reveal challenges, including a negative return on equity and a decline in revenue, which can influence brand perception among investors. The stock has also experienced volatility over the past year.

uniQure NV has 266 institutional owners and shareholders holding a total of 63,642,399 shares. Major institutional owners include Fmr Llc, Avoro Capital Advisors LLC, Rtw Investments, Lp, EcoR1 Capital, LLC, Aberdeen Group plc, Franklin Resources Inc, BlackRock, Inc., State Street Corp, Jennison Associates Llc, and Tekla Healthcare Investors. Aberdeen Group plc held the largest institutional position as of December 31, 2025, with 3.68 million shares, equating to 6.87% of the company. Overall, institutional investors hold approximately 86.04% of uniQure N.V. stock, while individual investors hold about 2.46%.